IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...

IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...

Annual Regulatory Oversight Report provides member firms with key insights and observations from its regulatory operations programs. The report covers fixtures such as financial crimes prevention, ...

WhiteBIT froze over $150M in funds, cooperating with law enforcement for some of the high-profile hacks in 2024.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

The US Department of Justice (DOJ)’s Attorney General, Pam Bondi, recently released over a dozen memoranda on a variety of policies – ranging ...

The Central Bank of the UAE (CBUAE) marked 2024 with significant achievements across the financial, banking, and insurance sectors. This further sets the stage for a bright future for the UAE's ...

An International Monetary Fund mission, led by Magnus Saxegaard, and comprising Christian Bogmans, Shinya Kotera, Yen Mooi, and Jonathan Pampolina conducted discussions for the 2025 Article IV ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.